Labiotech.eu

News and Trends 6 Jul 2022

Finnish and US companies form exclusive agreement for development of sustained release drug

A sustained release drug that can help people with age-related macular degeneration (AMD) has been given a global license agreement. DelSiTech and Iveric Bio have announced the agreement so Iveric Bio can develop and commercialize new formulations of drug Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion […]

July 6, 2022 - 4 minutesmins - By Liza Laws

News and Trends 6 Jul 2022

Exyte Builds mRNA Competence Center for WACKER in Germany

A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site of German company Wacker Chemie AG (WACKER). Exyte GmbH is a global design, engineering company that delivers facilities for high-tech industries and is in charge of the site at WACKER. The project is making a considerable contribution towards strengthening the […]

July 6, 2022 - 4 minutesmins - By Liza Laws

News and Trends 6 Jul 2022

New discovery center to house scientists opens in India

A discovery services center spanning 100,000 sq ft has been set up in Pune, India, to house a talent of chemists, biologists and formulation scientists. TCG Lifesciences Pvt. Limited (TCGLS), in charge of facilitating the center, is a global contract research and contract development and manufacturing company delivering research and development services in the pharmaceutical […]

July 6, 2022 - 2 minutesmins - By Liza Laws

Liver body Promethera decade3d anatomy online 1

News and Trends 5 Jul 2022

Poxel publishes ALD studies

Two preclinical articles have been published in different journals for treatments being developed by French biopharmaceutical company, Poxel. Poxel develops treatments for chronic, serious diseases with metabolic pathophysiology including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The articles have been about genetic disease X-Linked Adrenoleukodystrophy (ALD) and molecules PXL065 and PXL770. These molecules have separate […]

July 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

Destiny Pharma announces start of new oral mucositis research program

Oral mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2 million cancer patients every year. Destiny Pharma plc, a clinical-stage biotech company focused on the development of novel medicines that can prevent life-threatening infections, has started a new research program on the condition. The research study will be […]

July 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Jul 2022

Sanofi Global Health launches 30 nonprofit medicines in low-income countries

Medicines specifically for the world’s most impoverished countries and at-risk populations have been produced and launched by Sanofi. The announcement was made at a global health stakeholders meeting in Paris. The standard of care medicines have formed the Impact brand which includes insulin, glibenclamide and oxaliplatin among others. A secure distribution of 30 Sanofi medicines […]

July 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS

EditForce, Inc. has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop and commercialize potential gene therapy products for a specific target disease related to the central nervous system (CNS) by utilizing EditForce’s pentatricopeptide repeat (PPR) protein platform technology. MTPC and EditForce aim to create potential novel pharmaceuticals for the […]

July 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Jul 2022

Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care

Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. The initiative aims to identify and implement solutions that empower patients to improve their heart health, and to […]

July 5, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 5 Jul 2022

Evotec completes acquisition of Rigenerand

An Italian-based cell therapy business has just been bought by Evotec SE, a German therapeutics company. Evotec just announced the strategic transaction to buy Rigenerand Srl, with the deal, signed in May 2022, now completed. Based out of Medolla, Italy, the cell technology company working in the field of cGMP manufacturing of cell therapies will […]

July 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

Mogrify and Astellas to address sensorineural hearing loss

Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss. Utilizing Mogrify’s direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair […]

July 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Jul 2022

Positive news from trial for drug to treat major depressive disorder

A company working on treatments for people with mental health issues has had positive feedback from the development program of an anti-depressant targeting major depressive disorder (MDD). ANeuroTech has just announced that after a successful pre-Investigational New Drug Application (IND) meeting, the US Food and Drug Administration (FDA) has given positive feedback on its […]

July 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

AstraZeneca adds to its treatments for blood cancer with $100M deal

AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure. The company will hand over $100 million for TeneoTwo, Inc. in an upfront payment that will include its phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, that is being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma. With the […]

July 5, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Finnish and US companies form exclusive agreement for development of sustained release drug

Exyte Builds mRNA Competence Center for WACKER in Germany

New discovery center to house scientists opens in India

Poxel publishes ALD studies

Destiny Pharma announces start of new oral mucositis research program

Sanofi Global Health launches 30 nonprofit medicines in low-income countries

EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS

Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care

Evotec completes acquisition of Rigenerand

Mogrify and Astellas to address sensorineural hearing loss

Positive news from trial for drug to treat major depressive disorder

AstraZeneca adds to its treatments for blood cancer with $100M deal

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!